title: Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.
abstract: Multiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) represent chronic, autoimmune demyelinating disorders of the central and peripheral nervous system. Although both disorders share some fundamental pathogenic elements, treatments do not provide uniform effects across both disorders. We aim at providing an overview of current and future disease-modifying strategies in these disorders to demonstrate communalities and distinctions. Intravenous immunoglobulins (IVIG) have demonstrated short- and long-term beneficial effects in CIDP but are not effective in MS. Dimethyl fumarate (BG-12), teriflunomide and laquinimod are orally administered immunomodulatory drugs that are already approved or likely to be approved in the near future for the basic therapy of patients with relapsing-remitting MS (RRMS) due to positive results in Phase III clinical trials. However, clinical trials with these drugs in CIDP have not (yet) been initiated. Natalizumab and fingolimod are approved for the treatment of RRMS, and trials to evaluate their safety and efficacy in CIDP are now planned. Alemtuzumab, ocrelizumab and daclizumab respresent monoclonal antibodies in advanced stages of clinical development for their use in RRMS patients. Attempts to study the safety and efficacy of alemtuzumab and B cell-depleting anti-CD20 antibodies, i.e. rituximab, ocrelizumab or ofatumumab, in CIDP patients are currently under way. We provide an overview of the mechanism of action and clinical data available on disease-modifying immunotherapy options for MS and CIDP. Enhanced understanding of the relative effects of therapies in these two disorders may aid rational treatment selection and the development of innovative treatment approaches in the future.
authors.affiliation: Department of Neurology, University of Münster, Münster, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Melzer
authors.forename: S G
authors.initials: SG
authors.lastname: Meuth
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D002464:Cell Migration Inhibition / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007167:Immunotherapy; D039441:Integrin alpha4 / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D009103:Multiple Sclerosis / Q000188:drug therapy*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy*; D049349:Receptors, Lysosphingolipid / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D049349:Receptors, Lysosphingolipid; D039441:Integrin alpha4
keywords: CIDP; immunosuppression; immunotherapy; multiple sclerosis
references.citation: Cochrane Database Syst Rev. 2001;(4):CD002002
references.pmid: 11687131
references.citation: Brain. 1996 Aug;119 ( Pt 4):1067-77
references.pmid: 8813271
references.citation: Trends Pharmacol Sci. 2008 Nov;29(11):558-65
references.pmid: 18804288
references.citation: Lancet Neurol. 2012 Feb;11(2):131-9
references.pmid: 22226929
references.citation: Lancet. 2012 Nov 24;380(9856):1829-39
references.pmid: 23122650
references.citation: Lancet. 2007 Aug 4;370(9585):389-97
references.pmid: 17679016
references.citation: J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):279-83
references.pmid: 23704316
references.citation: Lancet Neurol. 2010 Mar;9(3):299-308
references.pmid: 20170843
references.citation: Cochrane Database Syst Rev. 2013 May 31;(5):CD002127
references.pmid: 23728638
references.citation: N Engl J Med. 2012 Sep 20;367(12):1098-107
references.pmid: 22992073
references.citation: N Engl J Med. 2012 Nov 22;367(21):2015-25
references.pmid: 23171098
references.citation: Lancet. 2012 Nov 24;380(9856):1819-28
references.pmid: 23122652
references.citation: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002062
references.pmid: 22895925
references.citation: Cochrane Database Syst Rev. 2010 May 12;(5):CD004678
references.pmid: 20464733
references.citation: Neurology. 2001 Feb 27;56(4):445-9
references.pmid: 11222785
references.citation: N Engl J Med. 2006 Mar 2;354(9):911-23
references.pmid: 16510745
references.citation: Lancet. 2009 Oct 31;374(9700):1503-11
references.pmid: 19815268
references.citation: Mult Scler. 2004 Feb;10(1):89-91
references.pmid: 14760960
references.citation: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005278
references.pmid: 18425915
references.citation: Neurology. 2006 Oct 10;67(7):1242-9
references.pmid: 16914693
references.citation: Lancet. 2004 Sep 25-Oct 1;364(9440):1149-56
references.pmid: 15451222
references.citation: Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006264
references.pmid: 18254098
references.citation: Ann Neurol. 2001 Aug;50(2):195-201
references.pmid: 11506402
references.citation: Lancet Neurol. 2012 Jun;11(6):493-502
references.pmid: 22578914
references.citation: Cochrane Database Syst Rev. 2012 Jan 18;1:CD005181
references.pmid: 22258960
references.citation: Arch Neurol. 2004 Sep;61(9):1409-12
references.pmid: 15364687
references.citation: J Neurol. 2008 Dec;255 Suppl 6:36-42
references.pmid: 19300958
references.citation: Cochrane Database Syst Rev. 2013 Jun 14;(6):CD003280
references.pmid: 23771584
references.citation: Lancet. 1998 Nov 7;352(9139):1491-7
references.pmid: 9820296
references.citation: N Engl J Med. 2008 Feb 14;358(7):676-88
references.pmid: 18272891
references.citation: Clin Exp Immunol. 2014 Mar;175(3):425-38
references.pmid: 24134716
references.citation: N Engl J Med. 2010 Feb 4;362(5):402-15
references.pmid: 20089954
references.citation: Clin Exp Immunol. 2014 Mar;175(3):397-407
references.pmid: 24102425
references.citation: Neurology. 2001 Jun 12;56(11):1496-504
references.pmid: 11402106
references.citation: Cochrane Database Syst Rev. 2004;(2):CD003208
references.pmid: 15106195
references.citation: Lancet. 2013 Jun 22;381(9884):2167-75
references.pmid: 23562009
references.citation: Cochrane Database Syst Rev. 2012 Dec 12;12:CD006921
references.pmid: 23235634
references.citation: Neurology. 2008 Jul 22;71(4):265-71
references.pmid: 18645164
references.citation: Lancet Neurol. 2008 Feb;7(2):136-44
references.pmid: 18178525
references.citation: Lancet Neurol. 2010 Apr;9(4):381-90
references.pmid: 20163990
references.citation: Neurology. 2010 Feb 23;74(8):651-7
references.pmid: 20177118
references.citation: Annu Rev Immunol. 2005;23:683-747
references.pmid: 15771584
references.citation: N Engl J Med. 2006 Mar 2;354(9):899-910
references.pmid: 16510744
references.citation: Lancet Neurol. 2009 Nov;8(11):987-97
references.pmid: 19748319
references.citation: Neurology. 1995 Jul;45(7):1268-76
references.pmid: 7617181
references.citation: Neurology. 2004 Dec 14;63(11):2028-33
references.pmid: 15596745
references.citation: Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003982
references.pmid: 17943809
references.citation: N Engl J Med. 2012 May 17;366(20):1870-80
references.pmid: 22591293
references.citation: Eur J Neurol. 2004 Nov;11(11):788
references.pmid: 15525302
references.citation: J Neurol Sci. 2007 May 15;256(1-2):100-2
references.pmid: 17382963
references.citation: J Neurol. 2010 Jun;257(6):913-9
references.pmid: 20049473
references.citation: J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):306-8
references.pmid: 20639381
references.citation: Lancet. 2002 Dec 21-28;360(9350):2018-25
references.pmid: 12504397
references.citation: Neurology. 2001 Jun 12;56(11):1505-13
references.pmid: 11402107
references.citation: N Engl J Med. 2005 Mar 31;352(13):1343-56
references.pmid: 15800230
references.citation: Lancet. 2011 Nov 19;378(9805):1779-87
references.pmid: 22047971
references.citation: Cochrane Database Syst Rev. 2012 Sep 12;(9):CD003906
references.pmid: 22972066
references.citation: N Engl J Med. 2011 Oct 6;365(14):1293-303
references.pmid: 21991951
references.citation: J Peripher Nerv Syst. 2013 Jun;18(2):130-40
references.pmid: 23781960
references.citation: N Engl J Med. 2012 Mar 15;366(11):1000-9
references.pmid: 22417253
references.citation: N Engl J Med. 2012 Sep 20;367(12):1087-97
references.pmid: 22992072
references.citation: N Engl J Med. 2010 Feb 4;362(5):387-401
references.pmid: 20089952
references.citation: Lancet. 1998 Nov 7;352(9139):1498-504
references.pmid: 9820297
references.citation: Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882
references.pmid: 23235682
references.citation: Arch Neurol. 2010 Jul;67(7):881-3
references.pmid: 20625098
references.citation: Neurology. 1999 Jul 13;53(1):57-61
references.pmid: 10408537
references.citation: Cochrane Database Syst Rev. 2013 Jun 06;(6):CD008933
references.pmid: 23744561
references.citation: N Engl J Med. 2000 Sep 28;343(13):898-904
references.pmid: 11006365
references.citation: Recent Pat CNS Drug Discov. 2012 Dec;7(3):218-29
references.pmid: 22742419
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002819
references.pmid: 17253481
references.citation: Ther Adv Neurol Disord. 2010 Mar;3(2):93-105
references.pmid: 21179602